Who
Ryan Savitz
EVP, CFO & Cbo
Company insider
Files Form 4 as: EVP, CFO & Cbo, Dianthus Therapeutics.
In numbers
- Trades disclosed
- 52
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $28.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 24 Jan 2024
- Last trade
- 9 Jul 2026
- Last filed
- 13 Jul 2026
Companies traded
Activity over time
1 Sep 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jul 2026filed 13 Jul 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $680K31,249 at $21.77 | filing |
| 9 Jul 2026filed 13 Jul 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M10,354 at $100.22 | filing |
| 9 Jul 2026filed 13 Jul 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M15,329 at $101.24 | filing |
| 9 Jul 2026filed 13 Jul 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,249 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $568K5,566 at $101.97 | filing |
| 9 Jul 2026filed 13 Jul 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,249 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $680K31,249 at $21.77 | filing |
| 9 Jul 2026filed 13 Jul 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M10,354 at $100.22 | filing |
| 9 Jul 2026filed 13 Jul 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M15,329 at $101.24 | filing |
| 9 Jul 2026filed 13 Jul 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $568K5,566 at $101.97 | filing |
| 9 Apr 2026filed 10 Apr 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $147K8,224 at $17.88 | filing |
| 9 Apr 2026filed 10 Apr 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $739K8,224 at $89.84 | filing |
| 9 Apr 2026filed 10 Apr 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,224 at $0.00 | filing |
| 9 Apr 2026filed 10 Apr 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,224 at $0.00 | filing |
| 9 Apr 2026filed 10 Apr 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $147K8,224 at $17.88 | filing |
| 9 Apr 2026filed 10 Apr 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $739K8,224 at $89.84 | filing |
| 31 Mar 2026filed 1 Apr 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $628K74,367 at $8.44 | filing |
| 31 Mar 2026filed 1 Apr 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $619K7,232 at $85.54 | filing |
| 31 Mar 2026filed 1 Apr 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —74,367 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
News
Analyzing Connect Biopharma (NASDAQ:CNTB) & Dianthus Therapeutics (NASDAQ:DNTH)DNTH · tickerreport.com · 22 Oct 2026Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaDNTH · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Ryan Savitz; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.